CMTx Biotech is focused on developing innovative therapies for rare and pandemic diseases. Their research centers around the repurposing of chemically-modified tetracycline (CMT) compounds for various therapeutic applications. CMTx Biotech's pipeline includes several promising drug candidates, each targeting a specific disease area. Their lead drug candidate, Incyclinide, has completed IND-enabling studies and has been tested safely in humans in other indications, accelerating its path to human clinical trials and market approval. By leveraging the known safety profile of tetracyclines and exploring new therapeutic applications, CMTx Biotech aims to address unmet medical needs and provide effective treatment options for patients with rare and pandemic diseases.

CMTx Biotech

Founded: 2019
Location: Stony Brook, New York
Employee range: 1-50
Clinical stage: Clin0
Therapy area: Septic shock, MODS, ARDS in sepsis patients
Drug types: INF, LNG
Lead product: Incyclinide (licensed from Galderma)
Funding: not disclosed

About:

Jobs: